{
    "fund_name": "VanEck Genomics and Healthcare Innovators UCITS ETF",
    "type": "ETF",
    "ucits": true,
    "leverage": false,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": [
        "Swaps",
        "Derivatives for non-EPM purposes"
    ],
    "classification": "complex",
    "supporting_data": "The KIID and factsheet indicate that while the ETF primarily uses physical replication, it also employs swaps (including equity swaps and total return swaps) and other derivatives such as futures, options, and non-deliverable forwards (NDFs). Although the ETF is UCITS-compliant and uses physical replication as its primary strategy, the use of swaps and derivatives beyond efficient portfolio management (EPM) introduces complexity. The presence of swap agreements and derivative instruments, even if not for leverage, suggests additional counterparty and operational risks that may not be easily understood by retail investors. The risk level is rated at 7, indicating high volatility, and the fund's concentration in specific sectors (genomics and healthcare) further adds to its complexity. The PRIIPs KID, if available, might include a comprehension warning, reinforcing the complexity classification.",
    "confidence": 85,
    "counter_argument": "The ETF could be argued as non-complex due to its UCITS compliance, physical replication, and lack of leverage or inverse strategies. However, the use of swaps and derivatives for purposes beyond simple replication or hedging (e.g., tracking error management or cost efficiency) introduces elements that require specialist knowledge, thus tipping the classification toward 'complex' under MiFID II.",
    "risk_level": 7,
    "primary_reasoning": "The primary factors driving the 'complex' classification are the use of swaps and derivatives beyond EPM, as well as the high risk profile (level 7) and sector concentration risks. These elements introduce additional layers of risk and operational complexity that may not be easily understood by retail investors."
}